Daiichi Sankyo has transferred 41 of its long-listed products to Alfresa Pharma.
The transaction also includes products manufactured by Daiichi Sankyos subsidiary Daiichi Sankyo Espha’. Alfresa Pharma will pay ¥8.42bn ($75.82m) to Daiichi Sankyo, as part of the transaction.
Daiichi Sankyo has also signed a licensing agreement with German immuno-oncology company, Glycotope, for the development of an antibody drug conjugate (ADC).
The company will combine its ADC technology with Glycotope’s investigational drug gatipotuzumab. It will also hold exclusive distribution rights to gatipotuzumab ADC, under the agreement.
Based in Japan, Daiichi Sankyo is a pharmaceutical company, while Alfresa Pharma, also based in Japan, is a pharmaceuticals and diagnostic products manufacturer.
MannKind has signed a distribution agreement with Tanner Pharma Group for its Afrezza® Inhalation Powder.
Tanner will become the exclusive distributor of Afrezza® in countries outside the US, under the agreement.
Available as a dry powder formulation, Afrezza® is a rapid-acting inhaled insulin product indicated for the treatment of Type 1 and Type 2 diabetes.
Based in the US, MannKind is a developer of therapeutic products, while Tanner Pharma, also based in the US, is a pharmaceutical company that commercialises healthcare products.
Dova Pharmaceuticals plans to issue securities through a public offering to raise $300m.
The company intends to issue the securities periodically in any combination of common stock, preferred stock, and warrants.
Cooley has been appointed as the legal adviser to the company for the offering.
Based in the US, Dova Pharmaceuticals is a pharmaceutical company engaged in the development of drug candidates for rare diseases.
The funds raised from the offering are intended to be used towards working capital and other general corporate purposes.
GlaxoSmithKline (GSK) has signed an agreement with 23andMe and made a $300m equity investment in the latter to leverage genetic insights for the development of novel medicines using human genetics.
The two companies have entered a four-year strategic partnership through which GSK will become the exclusive collaborator for 23andMe’s drug target discovery programmes.
Based in the UK, GSK is a pharmaceutical company engaged in the research and development of vaccines and healthcare products, while 23andMe is a genomics and biotechnology company based in the US.
The collaboration will enable the two companies to develop innovative drug targets and therapies for unmet medical needs.
EyePoint Pharmaceuticals plans to raise funds through a public offering of 49.46 million shares of its common stock.
Hogan Lovells US has been appointed as the legal adviser to the company for the offering.
Based in the US, EyePoint Pharmaceuticals is a specialist pharmaceutical company engaged in the development of innovative drug products.
